Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Lean Efficacy Phase IIa Proof of Concept Trial (LEAAP). A Study in Overweight and Obese Patients During Twenty-six Weeks, Investigating the Effect of EMP16-02 on Body Weight, Safety and Clinical Biomarkers

NCT04521751 is registered in ClinicalTrials.gov with Empros Pharma AB as lead sponsor.

NCT NCT04521751
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04521751 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Lean Efficacy Phase IIa Proof of Concept Trial (LEAAP). A Study in Overweight and Obese Patients During Twenty-six Weeks, Investigating the Effect of EMP16-02 on Body Weight, Safety and Clinical Biomarkers
Lead sponsor
Empros Pharma AB
Phase
Phase 1/2
Overall status
Completed
Start date
May 7, 2020
Completion date
August 30, 2021
Enrollment
156 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

overweight or obesity